Earlier we reported publication of the first results of the Diagnode-1 and Diagnode-2 studies, testing Diamyd Medical's diabetes vaccine GAD-alum (Diamyd®) in people with recently diagnosed type 1 diabetes. Diamyd Medical is now recruiting people for the Diagnode 3 study.
Recently a consensus statement on the use of open-source insulin delivery (AID) systems was published. Diabeter pediatrician Per Winterdijk, himself an open-source AID system user, contributed to the statement